New chemo cocktail shows promise in myeloma stem cell transplants

NCT ID NCT01702831

Completed Disease control Sponsor: University Health Network, Toronto Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 study tested a combination of two chemotherapy drugs, busulfan and melphalan, given before an autologous stem cell transplant in 78 people with newly diagnosed multiple myeloma. All participants had already received a bortezomib-based induction therapy and then took lenalidomide maintenance after transplant until the disease worsened. The main goal was to see how many patients had no detectable cancer cells (minimal residual disease negativity) 100 days after transplant.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Busulfan and melphalan (chemotherapy drugs)
What this could lead to: If successful, this combination could improve the depth of response after stem cell transplant and help keep multiple myeloma under control for longer.
What could go wrong: This is a small, single-arm phase 2 study, so results may not apply broadly. Chemotherapy side effects can be serious, and the disease may still return despite maintenance therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

Cross Cancer Institute 11560 University Ave

Edmonton, Alberta, T6G-1Z2, Canada
Hôpital Maisonneuve-Rosemont, 5415, boul. de l'Assomption

Montreal, Quebec, H1T 2M4, Canada
London Regional Cancer Program 790 Commissioners Road East

London, Ontario, N6A 4L6, Canada
Princess Margaret Cancer Centre

Toronto, Ontario, M5G 2M9, Canada
Queen Elizabeth II Health Sciences Centre.

Halifax, Nova Scotia, B3H 2Y9, Canada
Royal Victoria Hospital, MUHC Glen Site, Cedars Cancer Centre

Montreal, Quebec, H4A 3J1, Canada
Saint John Regional Hospital, 5DN Research Department, 400 University Ave

Saint John, New Brunswick, E2L 4L2, Canada
Saskatoon Cancer Centre 20 Campus Drive

Saskatoon, Saskatchewan, S7N 4H4, Canada
The Ottawa Hospital

Ottawa, Ontario, K1H 8L6, Canada
Vancouver General Hospital, Centennial Pavilion, 6th Floor

Vancouver, British Columbia, V5Z 1M9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.